The Institute of Cancer Policy (ICP) brings together the world’s largest global cancer research and policy faculty co-ordinated between King’s College London and London School of Hygiene & Tropical Medicine. The ICP works closely with UK Global Cancer Network and its global partners conducting policy evaluations, global cancer research and capacity building. The ICPs mission is to support the development of more affordable, equitable and high-quality cancer care and research across the world, particularly to support partners and countries to address some of the most challenging issues facing cancer control today, from conflict to economic sustainability.

The ICP has developed deep experience, expertise and evidence across complex health settings and system challenges for cancer control. We integrate advanced transdisciplinary research methods from epidemiology, economic and political sciences through to implementation science and health systems research. Community and patient involvement and understanding the broader social determinants of cancer is a central strategic pillar. The ICP has led over 15 Lancet and Lancet Oncology global cancer Commissions in the last decade as well as over 20 major global research programs.

The ICP has advised and conducted strategic insight research for national governments, the World Health Organisation, international research and economic bodies as well as humanitarian organisations. We also support a number of international cancer organisations to provide strategic global cancer intelligence in support of their work.

Active projects

• Lancet Oncology US Cancer Moonshot Commission. In a follow up to the first Moonshot commission the ICP is working with colleagues to examine national workforce challenges across Sub Saharan Africa and Latin America in the context of the Biden Moonshot program.
• Cancer in Crisis Lancet Oncology Commission. The ICP is co-leading this Commission with Global Institute of Psychosocial, Palliative & End-of-Life Care (GIPPEC) at Princess Margaret Hospital, Toronto to critical understand major issues in global cancer in light of multiple intersecting global challenges.
• Global Quality Indicators (QI) for Cancer Care for City Cancer Challenge. Currently in phase II (examining cancer quality indicators for cancer pathology, imaging, palliative care and financing) the ICP continues its groundbreaking work on QI in support of C/CAN’s wider mission.
• Commonwealth Lancet Oncology Commission. Initiated in 2024 the ICP is contributing to two workstreams of this new Commission.
• National cancer control planning for the UK. The ICP has co-led major strategic reviews and analysis into the UK’s national cancer control plans. Currently an in-depth examination of the strategic direction of UK cancer R&D is underway. Within this work the ICP have developed tools to inform cancer service planning https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00398-9/fulltext
• Cancer care in humanitarian settings (R4HC/R4HSSS). Following on from the recently published WHO-endorsed Manifesto following the joint ICP (King’s College London) / WHO UN NCD cancer in humanitarian settings meeting we are working with partners to develop high level operational engagement
• GACD funded multi-cancer early detection implementation science - Access Cancer Care India. Now in its 3^rd year in collaboration with cancer leaders from India and WHO IARC this multi-site implementation science program continues its work to develop new models for early detection of high burden multiple cancers.
• Augmenting pelvic surgery training through virtual reality surgical simulation (VRSS) supported by Rosetrees Foundation/BASO. Our partnership with Zambian and Southern Methodist University (USA) colleagues to develop has now reached clinical development and validation stages.
• Supporting surgical oncology capacity development in Zambia. We are working to support Zambian colleagues in the development of a cancer surgical capacity plan, focused on pelvic (cervical cancer) and general surgery (breast cancer as well as broader research capacity plan.
• Supporting research prioritisation for cancer to inform national cancer control planning. We supported Zambian and Ugandan colleagues using a Delphi methodology to develop a key set of research priorities for prostate cancer care. https://bmjoncology.bmj.com/content/bmjonc/3/1/e000172.full.pdf
• ICP support several national and international Value based healthcare initiatives. As co-chair of the Health Economics in Radiation Oncology group within the European Society of Radiation Oncology, Ajay Aggarwal is one of the leaders of the value-based health care programs designed to support responsible and timely adoption of evidence based technologies. https://www.estro.org/Advocacy/ECF/Value-Based-HealthCare-(VBHC)
• Common Sense Oncology. As founding partners ICP continues to support core activities of CSO in particular on wider biopharmaceutical public policy. We currently have active projects on medicines regulatory policy in Brazil and European Union.
• Therapeutic geographies (TG) of cancer. Working with colleagues in the Middle East we are expanding our international work to look at how patients and care alter across national boundaries in response to insecurity, conflict and fragility. This work is closely tied to the world leading expertise in studying the TG of cancer patients across the UK.
• Building global resilience against Disease X into global cancer services & systems. Following the work of the COVID-19 and Cancer Global Taskforce co-led by the ICP and in collaboration with biosecurity experts through King’s Centre for Conflict & Health Research we are continuing our work to understand critical impact and mitigation strategies for cancer systems to future pandemics and building this intelligence into the work of the International Partnership for Resilience in Cancer Systems (IPaRCS).
• Trial evaluation of Artificial Intelligence for radiotherapy treatment. The ARCHERY study led by Ajay Aggarwal is the first prospective international trial across India, South Africa, Jordan and Malaysia evaluating the role of AI in radiotherapy with multiple partners include the Medical Research Council and MD Anderson Cancer Center.
• Quality Assessment and Assurance of Cancer Care – Ajay Aggarwal is the Clinical Director of the UK National Cancer Audit Collaborating Centre NATCAN oversee 10 national audits of cancer care, covering all public sector hospitals in the England and Wales NHS.
• Collabortive centre to WHO and provision of technical advice to key workstreams related to Noncommunicable diseases and cancer, including Global Cervical Cancer Screening and Treatment Guideline Development Group and Global Breast Cancer Initiative.
• Partner to the International Cancer Control Partnership and currently conducting a number of sub-analyses following the recent global review of NCCPs.

Media & Meetings

• ICP at the European Cancer Summit 2023 discussing conflict and cancer
• The UK’s failure to provide a coherent cancer plan. ICP commentary in Guardian
• ICP at the joint EMA / EORTIC Optimising Drug Development meeting in April 2024. How to better develop public policy for academic clinical trials
• ICP supported BMJ examination into issues with multi-cancer early detection test GrAiL
• ICP quoted in Men’s Health magazine article on early onset cancer
• Julie Torode, Ajay Aggarwal and Richard Sullivan will be presenting research and policy at the World Cancer Congress in Geneva in September 2024, covering global can cer surgery, cancer care in humanitarian settings, global cancer quality agenda, amongst many other topics.